No Cancer Link Found in Incretin Meds
Some data have suggested that incretin-based medications—DPP-4 inhibitors, such as sitagliptin (Januvia), and GLP-1 agonists, such as exenatide (Byetta)—are associated with the development of pancreatitis and pancreatic cancer. Over the past year, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) independently evaluated the safety of these medications using all the available data, including studies in both animals and humans. The FDA and EMA said that the evidence did not support the claim that incretin-based medications cause pancreatitis or pancreatic cancer, though the agencies will continue to study the safety of these medications.
Source: The New England Journal of Medicine, Feb. 27, 2014